"uuid:ID","versionIdentifier","id","instanceType","rationale"
"b40be9fb-180a-481d-b3ad-29e0e5c5bd0e","2","StudyVersion_1","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
